<SEC-DOCUMENT>0001171843-19-005865.txt : 20190909
<SEC-HEADER>0001171843-19-005865.hdr.sgml : 20190909
<ACCEPTANCE-DATETIME>20190909090146
ACCESSION NUMBER:		0001171843-19-005865
CONFORMED SUBMISSION TYPE:	SC 13E3/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20190909
DATE AS OF CHANGE:		20190909

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Capstone Therapeutics Corp.
		CENTRAL INDEX KEY:			0000887151
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				860585310
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13E3/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-42745
		FILM NUMBER:		191081245

	BUSINESS ADDRESS:	
		STREET 1:		1275 WEST WASHINGTON STREET
		STREET 2:		SUITE 101
		CITY:			TEMPE
		STATE:			AZ
		ZIP:			85281
		BUSINESS PHONE:		6022865520

	MAIL ADDRESS:	
		STREET 1:		1275 WEST WASHINGTON STREET
		STREET 2:		SUITE 101
		CITY:			TEMPE
		STATE:			AZ
		ZIP:			85281

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHOLOGIC CORP
		DATE OF NAME CHANGE:	19940211

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Capstone Therapeutics Corp.
		CENTRAL INDEX KEY:			0000887151
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				860585310
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13E3/A

	BUSINESS ADDRESS:	
		STREET 1:		1275 WEST WASHINGTON STREET
		STREET 2:		SUITE 101
		CITY:			TEMPE
		STATE:			AZ
		ZIP:			85281
		BUSINESS PHONE:		6022865520

	MAIL ADDRESS:	
		STREET 1:		1275 WEST WASHINGTON STREET
		STREET 2:		SUITE 101
		CITY:			TEMPE
		STATE:			AZ
		ZIP:			85281

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHOLOGIC CORP
		DATE OF NAME CHANGE:	19940211
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13E3/A
<SEQUENCE>1
<FILENAME>sc13e3a_090919.htm
<DESCRIPTION>SC 13E3/A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>UNITED STATES</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Washington, D.C. 20549</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>______________________________________________<BR>
<BR>
</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SCHEDULE 13E-3</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e)</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>OF THE SECURITIES EXCHANGE ACT OF 1934<BR>
</B>(Amendment No. 2)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>______________________________________________<BR>
<BR>
</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CAPSTONE THERAPEUTICS CORP.<BR>
</B>(Name of the Issuer and Name of Person Filing Statement)<BR>
<B>______________________________________________<BR>
<BR>
</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Common Stock, par value $0.0005 per share</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Title of Class of Securities)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>14068E109</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(CUSIP Number of Class of Securities)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Les M. Taeger</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Senior Vice President, Chief Financial Officer</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Capstone Therapeutics Corp.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>1275 W. Washington Street, Suite 104</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Tempe, Arizona 85281<BR>
(602) 286-5520</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Name, Address and Telephone Number of Person Authorized to</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Receive Notices and Communications on Behalf of the Person Filing
Statement)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><BR>
With copies to:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Daniel M. Mahoney</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Joshua Schneiderman</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Snell &amp; Wilmer L.L.P.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>One Arizona Center</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>400 East Van Buren</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Phoenix, Arizona 85004</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>(602) 382-6000</B>&nbsp;<BR>
<B>______________________________________________</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">This statement is filed in connection with (check the appropriate box):</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">a. </FONT>[X]</TD><TD><FONT STYLE="font-size: 10pt">The filing of solicitation materials or an information statement subject to Regulation 14A, Regulation<BR>
14C or Rule 13e-3(c) under the Securities Exchange Act of 1934.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">b. </FONT>[_]</TD><TD><FONT STYLE="font-size: 10pt">The filing of a registration statement under the Securities Act of 1933.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">c. </FONT>[_]</TD><TD><FONT STYLE="font-size: 10pt">A tender offer.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">d. </FONT>[_]</TD><TD><FONT STYLE="font-size: 10pt">None of the above.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><BR>
Check the following box if the soliciting materials or information statement referred to in checking box (a) are preliminary copies.
</FONT>[_]<FONT STYLE="font-size: 10pt"><BR>
<BR>
</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Check the following box if the filing is a final amendment
reporting the results of the transaction. </FONT>[X]</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><BR>
Calculation of Filing Fee</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 50%; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">TRANSACTION VALUATION*</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">AMOUNT OF FILING FEE**</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #EEEEEE">
    <TD STYLE="border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">$10,000</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">$2</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">* Calculated solely for the purposes of determining the filing fee.
The transaction valuation assumes the payment for 379,000 shares of common stock of the Company at $.025 per share in cash (or
the closing price of the Company&rsquo;s common stock on the OTCQB on May 29, 2019), in lieu of issuing fractional shares to holders
of less than 1,000 shares of common stock. Actual amounts paid for fractional shares will equal the Cash-Out-Payment (as defined
herein).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">** The filing fee is calculated in accordance with Rule 0-11(b)
by multiplying the Transaction Valuation by 0.0001212.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">[X] <FONT STYLE="font-size: 10pt">Check the box if any part of the
fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously
paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 20pt">Amount Previously Paid: $2</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 20pt">Form or Registration No.: Schedule 13E-3 (File No. 005-42745)</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 20pt">Filing Party: Capstone Therapeutics Corp.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 20pt">Date Filed: May 31, 2019</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Introduction</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">This Amendment No. 2 to Rule 13e-3 Transaction
Statement on Schedule 13E-3 (as amended, the &ldquo;Schedule 13E-3&rdquo;), is being filed by Capstone Therapeutics Corp., a Delaware
corporation (the &ldquo;Company&rdquo;), in connection with a proposed going private transaction. The Schedule 13E-3 was initially
filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on May 31, 2019 and was subsequently amended by Amendment
No. 1 filed on July 3, 2019. This Amendment No. 2 is being filed pursuant to Rule 13e-3(d)(3) of the Securities Exchange Act of
1934, as amended (the &ldquo;Exchange Act&rdquo;), as a final amendment to the Schedule 13E-3 solely to report the results of the
Rule 13e-3 transaction.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">At the Company&rsquo;s 2019 Annual Meeting of
Stockholders held on August 22, 2019, the Company&rsquo;s stockholders approved an amendment to the Company&rsquo;s Amended and
Restated Certificate of Incorporation (the &ldquo;Certificate of Amendment&rdquo;) to effect a 1-for-1,000 reverse stock split
of the Company&rsquo;s common stock, par value $0.0005 per share (the &ldquo;Common Stock&rdquo;), resulting in (i) holdings prior
to such split of fewer than 1,000 shares of Common Stock being converted into a fractional share, which were immediately cancelled
and converted into a right to receive the &ldquo;Cash-Out-Payment&rdquo; as described in the Company&rsquo;s definitive proxy statement
on Schedule 14A filed with the SEC on July 10, 2019, and (ii) the Company having fewer than 300 stockholders of record, thereby
allowing the Company to deregister its Common Stock under the Exchange Act and avoid the costs associated with being a public reporting
company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">On August 22, 2019, the Company filed with the
Secretary of State of the State of Delaware the Certificate of Amendment to effect the reverse stock split.&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Company, upon completion of the reverse
stock split and verification that the Company has fewer than 300 stockholders of record, intends to file a Form 15 with the SEC
to deregister the Common Stock under the Exchange Act. Upon filing of the Form 15, the Company&rsquo;s obligation to file certain
reports with the SEC, including Forms 10-K, 10-Q and 8-K, will be immediately suspended. The Company expects that the deregistration
will become effective 90 days after the date of filing of the Form 15.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SIGNATURE</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">After due inquiry and to the best of its knowledge and belief, the
undersigned certifies that the information set forth in this statement is true, complete and correct.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 49%; font-size: 10pt; font-weight: bold; text-align: left">CAPSTONE THERAPEUTICS CORP.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">By: <U>/s/ John M. Holliman, III&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Name: John M. Holliman, III</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Title: Executive Chairman</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Dated: September 9, 2019</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
